Loading...
XNASORMP
Market cap95mUSD
Dec 27, Last price  
2.37USD
1D
0.42%
1Q
-4.44%
Jan 2017
-61.27%
Name

Oramed Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ORMP chart
P/E
17.29
P/S
71.30
EPS
0.14
Div Yield, %
0.00%
Shrs. gr., 5y
22.21%
Rev. gr., 5y
-11.36%
Revenues
1m
-50.43%
0000000197,412184,254000641,0002,456,0002,449,0002,703,0002,710,0002,703,0002,703,0001,340,000
Net income
6m
P
-720,000-45,781-414,576-3,236,000-2,769,271-2,760,474-2,977,376-1,561,245-3,344,478-4,231,812-5,696,000-7,232,000-10,964,000-10,480,000-12,727,000-14,355,000-11,511,000-22,238,000-37,764,0005,525,000
CFO
-10m
L-63.12%
-290,000-40,435-361,613-611,000-1,836,958-2,268,923-1,418,472-1,666,037-2,301,608-3,395,341-4,068,000-4,946,0004,655,000-5,831,000-14,657,000-12,940,000-12,440,000-21,181,000-27,918,000-10,295,000
Earnings
Mar 04, 2025

Profile

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
URL
https://oramed.com/
IPO date
Apr 01, 2002
Employees
13
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑082020‑082019‑082018‑082017‑082016‑082015‑08
Income
Revenues
1,340
-50.43%
2,703
0.00%
Cost of revenue
17,109
43,301
Unusual Expense (Income)
NOPBT
(15,769)
(40,598)
NOPBT Margin
Operating Taxes
100
Tax Rate
NOPAT
(15,769)
(40,698)
Net income
5,525
-114.63%
(37,764)
69.82%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,428
11,500
BB yield
-2.59%
-2.45%
Debt
Debt current
51,280
247
Long-term debt
951
1,541
Deferred revenue
4,000
4,000
Other long-term liabilities
102
82
Net debt
(166,182)
(156,632)
Cash flow
Cash from operating activities
(10,295)
(27,918)
CAPEX
(254)
(496)
Cash from investing activities
(73,038)
30,211
Cash from financing activities
51,978
10,779
FCF
(15,527)
(41,575)
Balance
Cash
162,047
155,720
Long term investments
56,366
2,700
Excess cash
218,346
158,285
Stockholders' equity
(157,999)
(163,261)
Invested Capital
376,616
319,393
ROIC
ROCE
EV
Common stock shares outstanding
40,567
38,998
Price
2.31
-80.80%
12.03
-38.87%
Market cap
93,710
-80.03%
469,142
-16.27%
EV
(73,400)
311,854
EBITDA
(15,573)
(40,540)
EV/EBITDA
4.71
Interest
3,580
2,934
Interest/NOPBT